` CYTK (Cytokinetics Inc) vs S&P 500 Comparison - Alpha Spread

CYTK
vs
S&P 500

Over the past 12 months, CYTK has underperformed S&P 500, delivering a return of -39% compared to the S&P 500's 9% growth.

Stocks Performance
CYTK vs S&P 500

Loading
CYTK
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CYTK vs S&P 500

Loading
CYTK
S&P 500
Difference
www.alphaspread.com

Performance By Year
CYTK vs S&P 500

Loading
CYTK
S&P 500
Add Stock

Competitors Performance
Cytokinetics Inc vs Peers

S&P 500
CYTK
ABBV
AMGN
GILD
VRTX
Add Stock

Cytokinetics Inc
Glance View

Economic Moat
None
Market Cap
3.9B USD
Industry
Biotechnology

Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs. As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.

CYTK Intrinsic Value
33.29 USD
Undervaluation 2%
Intrinsic Value
Price
Back to Top